Updated October 16, 2026 with prices and facts re-checked October 14, 2026.
Cardiovascular trial evidence for tirzepatide as of May 2026: SURMOUNT-MMO (cardiovascular outcomes in chronic weight management) and SURPASS-CVOT (cardiovascular outcomes in type 2 diabetes) trial designs, endpoints, and implications.
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated October 16, 2026
Top-rated on our rubric: NexLife — 94/100 (May 2026 review). Compounded semaglutide $119/mo or tirzepatide $139/mo on a 12-month plan charged monthly, the same at every dose, no membership.Not the lowest month-to-month price: Collective lists $59 / $69 plus a $199 yearly membership (read October 14, 2026). Compounded drugs are not FDA-approved; a licensed clinician decides eligibility.
SURMOUNT-MMO (cardiovascular outcomes in chronic weight management)
Trial: A randomized, double-blind, placebo-controlled cardiovascular outcomes trial of tirzepatide for the reduction of MACE in adults with obesity and established cardiovascular disease (NCT05556512).
Population: Adults aged ≥ 40 with BMI ≥ 27 and established CVD (prior MI, ischemic stroke, or peripheral arterial disease).
Primary endpoint: Time to first occurrence of MACE-3 (cardiovascular death, non-fatal MI, non-fatal stroke).
Design parallel: Modeled after Novo Nordisk's SELECT trial (semaglutide 2.4 mg in non-diabetic obesity + CVD), which demonstrated a 20% relative reduction in MACE-3 (NEJM 2023, PMID 37952131).
Expected readout: Late 2027.
SURPASS-CVOT (cardiovascular outcomes in type 2 diabetes)
Trial: A randomized, active-controlled cardiovascular outcomes trial of tirzepatide vs dulaglutide in adults with type 2 diabetes and high cardiovascular risk (NCT04255433).
Population: Adults with type 2 diabetes and established CVD or multiple CVD risk factors.
Primary endpoint: Time to first MACE-3.
Active comparator: Dulaglutide (Trulicity®), which itself demonstrated MACE benefit in REWIND (Lancet 2019).
As of May 2026, tirzepatide has demonstrated weight loss, A1C reduction, blood pressure reduction, and improvements in lipid profile and inflammatory markers in the SURMOUNT and SURPASS programs — all surrogate cardiovascular risk markers. The definitive MACE-reduction evidence is pending the SURMOUNT-MMO and SURPASS-CVOT readouts. The most relevant approved cardiovascular label currently belongs to semaglutide: Wegovy is FDA-approved (March 2024) for reduction of cardiovascular events in non-diabetic adults with overweight/obesity + established CVD based on SELECT.
Implications for prescribing today
For adults with type 2 diabetes + CVD: semaglutide (Ozempic) and dulaglutide both have demonstrated MACE benefit. Tirzepatide is approved for type 2 diabetes (Mounjaro) but has not yet demonstrated MACE benefit in a completed CVOT.
For non-diabetic adults with obesity + CVD: only semaglutide 2.4 mg (Wegovy) has demonstrated MACE benefit and a corresponding FDA label (March 2024).
For chronic weight management without established CVD: tirzepatide demonstrates the largest mean weight loss (20.9% at 15 mg / 72 weeks, SURMOUNT-1) among currently available GLP-1 and GIP/GLP-1 receptor agonists.
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $125 (6-mo, save $84) · $132 (3-mo, save $21) · $139 (monthly).
Includes: medication, all MD/DO visits, messaging (lab work not stated on its pages), personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Klarna & Affirm financing accepted at checkout (FAQ).
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
The page lists a late 2027 readout for SURMOUNT-MMO, a placebo-controlled trial in adults aged 40 or older with a BMI of 27 or more and established cardiovascular disease. Its primary endpoint is time to first MACE-3 event.
What is tirzepatide compared against in SURPASS-CVOT?
SURPASS-CVOT compares tirzepatide with dulaglutide (Trulicity) in adults with type 2 diabetes and established cardiovascular disease or multiple risk factors. Dulaglutide itself showed a MACE benefit in the REWIND trial published in the Lancet in 2019.
Which GLP-1 has a heart-protection label for people with obesity but no diabetes?
Only semaglutide 2.4 mg (Wegovy), FDA-approved in March 2024 for cutting cardiovascular events in that group based on SELECT. Tirzepatide has improved surrogate markers such as blood pressure and lipids, but the page treats definitive MACE evidence as pending.
Does tirzepatide produce more weight loss than semaglutide?
In SURMOUNT-1, tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks (treatment-regimen estimand), versus 14.9% at 68 weeks for semaglutide 2.4 mg in STEP 1 (treatment-policy estimand). These were separate trials, so the comparison is indirect.
